Edward M. Kaye MD sold $164k of STOK
CEO at Stoke Therapeutics, Inc.. 19,289 shares at an average of $8.49, traded Mar 18, 2025, filed Mar 20, 2025.
Score components
- +15RoleDirector
- +11Trade size$164k at market
- +5Share of holdings soldSold 12% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-008711, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 18, 2025 | SOpen-market sale Common Stock | -10,382 | $8.67 | $90k | 148,253 | Mar 20, 2025 |
| Mar 19, 2025 | SOpen-market sale Common Stock | -8,907 | $8.27 | $74k | 139,346 | Mar 20, 2025 |
| Mar 20, 2025 | AGrant or award Employee Stock Option (Right to Buy)derivative | +216,000 | $0.00 | $0 | 216,000 | Mar 20, 2025 |
| Mar 20, 2025 | AGrant or award Restricted Stock Unitsderivative | +144,000 | $0.00 | $0 | 144,000 | Mar 20, 2025 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 25Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $445k 22,117 shares | -89% | |
| 38Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $1.2M 61,885 shares | -40% | |
| 28Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $31k 1,683 shares | -7% | |
| 35Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $221k 12,126 shares | -7% | |
| 25Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $206k 13,712 shares | -41% | |
| 55Moderate | Stoke Therapeutics, Inc. | Skorpios Trust owner | $31M 3,000,000 shares | -43% | |
| 17Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $82k 8,216 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.